Lakefront Biotherapeutics NV
GLPGF
$26.24
-$1.84-6.55%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -81.34% | -90.57% | 1,321.15% | -11.60% | -11.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.34% | -90.57% | 1,321.15% | -11.60% | -11.60% |
| Cost of Revenue | -17.52% | -80.15% | 12.44% | -50.56% | 16.92% |
| Gross Profit | -198.63% | 73.72% | 2,529.48% | 297.31% | -197.53% |
| SG&A Expenses | 60.85% | -11.60% | -4.92% | -55.22% | -2.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 81.27% | 82.10% | -131.03% | -21.27% | -21.27% |
| Total Operating Expenses | 16.52% | -67.25% | -6.84% | -56.37% | 11.13% |
| Operating Income | -353.37% | 56.23% | 1,604.41% | 147.70% | -57.49% |
| Income Before Tax | 101.94% | 109.73% | 4,236.05% | -2,792.15% | -2,792.15% |
| Income Tax Expenses | 170.85% | 104.21% | 1,945.95% | 104.80% | 104.80% |
| Earnings from Continuing Operations | 101.87% | 109.80% | 4,223.72% | -2,462.93% | -2,462.93% |
| Earnings from Discontinued Operations | 112.79% | -42.54% | -109.33% | -131.65% | -131.65% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.01% | 110.30% | 3,492.13% | -1,341.01% | -1,341.01% |
| EBIT | -353.37% | 56.23% | 1,604.41% | 147.70% | -57.49% |
| EBITDA | -218.87% | 59.74% | 2,192.31% | 228.72% | -40.46% |
| EPS Basic | 102.01% | 110.30% | 3,489.35% | -1,340.35% | -1,340.35% |
| Normalized Basic EPS | -176.27% | 81.84% | -- | 175.81% | -202.03% |
| EPS Diluted | 102.00% | 110.30% | 3,502.16% | -1,340.35% | -1,340.35% |
| Normalized Diluted EPS | -176.07% | 81.84% | -- | 176.15% | -203.35% |
| Average Basic Shares Outstanding | -0.09% | 0.05% | 0.01% | 0.02% | 0.02% |
| Average Diluted Shares Outstanding | 0.12% | 0.05% | -0.03% | -0.43% | -0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |